University of California San Francisco

Publications

Selected Publications
  1. Letter: Commentary: Trans-Sternal Multilevel Corpectomy for Cervicothoracic Renal Cell Metastasis: 2-Dimensional Operative Video.
    2024 | PubMed
  2. Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling.
    2024 | UCSF Research Profile
  3. 8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers.
    2024 | UCSF Research Profile
  4. Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.
    2024 | UCSF Research Profile
  5. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    2024 | PubMed
  6. A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
    2024 | PubMed
  7. Trans-Sternal Multilevel Corpectomy for Cervicothoracic Renal Cell Metastasis: 2-Dimensional Operative Video.
    2024 | PubMed
  8. Quantitative Polymerase Chain Reaction and Precision Medicine.
    2023 | UCSF Research Profile
  9. Treatments for dengue: a Global Dengue Alliance to address unmet needs.
    2023 | PubMed
  10. PET Standardized Uptake Value May Influence Surgical Planning for Clinical Stage IA Non-Small Cell Lung Cancer.
    2023 | PubMed
  11. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer.
    2023 | UCSF Research Profile
  12. Transcriptional space-time mapping identifies concerted immune and stromal cell patterns and gene programs in wound healing and cancer.
    2023 | PubMed
  13. 287 Genomic and Immunologic Characterization of Lung Adenocarcinoma in Never Smokers vs. Smokers.
    2023 | UCSF Research Profile
  14. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas.
    2023 | PubMed
  15. SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants.
    2023 | PubMed
  16. Tracheal Reconstruction Using Endotracheal Stent and Pectoralis Major Muscle Flap.
    2022 | PubMed
  17. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.
    2022 | PubMed
  18. Discovering dominant tumor immune archetypes in a pan-cancer census.
    2021 | PubMed
  19. Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
    2021 | PubMed
  20. Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic.
    2021 | PubMed
  21. Perioperative Lung Resection Outcomes After Implementation of a Multidisciplinary, Evidence-based Thoracic ERAS Program.
    2021 | PubMed
  22. Multiomic Characterization of Stage I Lung Adenocarcinoma Reveals Distinct Genetic and Immunologic Features of Recurrent Disease.
    2021 | UCSF Research Profile
  23. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
    2021 | PubMed
  24. P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results.
    2021 | UCSF Research Profile
  25. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
    2021 | PubMed
  26. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    2021 | PubMed
  27. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
    2021 | PubMed
  28. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    2021 | PubMed
  29. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator.
    2021 | PubMed
  30. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity.
    2021 | PubMed
  31. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
    2021 | PubMed
  32. Bioinformatic Approaches to Validation and Functional Analysis of 3D Lung Cancer Models.
    2021 | PubMed
  33. Commentary: Cardiothoracic surgery training: Global challenges without universal solutions.
    2021 | PubMed
  34. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy.
    2021 | UCSF Research Profile
  35. Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.
    2020 | PubMed
  36. Delaying surgery for patients with a previous SARS-CoV-2 infection.
    2020 | PubMed
  37. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
    2020 | PubMed
  38. Pulmonary Embolus of Benign Liver Tissue Following Partial Hepatectomy.
    2020 | UCSF Research Profile
  39. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.
    2019 | PubMed
  40. Esophagectomy Outcomes after Implementation of an Enhanced Recovery after Surgery Program.
    2019 | UCSF Research Profile
  41. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC.
    2019 | UCSF Research Profile
  42. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer.
    2019 | UCSF Research Profile
  43. Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.
    2019 | PubMed
  44. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    2019 | PubMed
  45. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    2019 | PubMed
  46. Quantitative Polymerase Chain Reaction for Companion Diagnostics and Precision Medicine Application.
    2019 | UCSF Research Profile
  47. Central Airway Obstruction Due to Tracheal Glomus Tumor.
    2018 | PubMed
  48. Giant right coronary artery aneurysm presenting as cardiac tamponade.
    2018 | PubMed
  49. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy.
    2018 | UCSF Research Profile
  50. P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    2018 | UCSF Research Profile
  51. Propensity Matched Analysis of Perioperative Outcomes in Robotic-Assisted Thoracic Surgery, Video Assisted Thoracic Surgery, and Open Lung Resections.
    2018 | UCSF Research Profile
  52. Intraoperative identification and treatment of a giant right coronary artery aneurysm.
    2018 | PubMed
  53. Surgical Management of Pulmonary Mucormycosis in Third-Trimester Pregnancy.
    2018 | PubMed
  54. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
    2017 | PubMed
  55. Management of Lung Cancer Invading the Superior Sulcus.
    2017 | PubMed
  56. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer.
    2017 | UCSF Research Profile
  57. P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: Staging.
    2017 | UCSF Research Profile
  58. High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation.
    2016 | PubMed
  59. High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation.
    2016 | PubMed
  60. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
    2015 | PubMed
  61. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    2015 | PubMed
  62. Prognostic and Predictive Biomarker Signatures.
    2014 | UCSF Research Profile
  63. The migrated liver transplantation candidate: insight into geographic disparities in liver distribution.
    2014 | PubMed
  64. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.
    2013 | PubMed
  65. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.
    2013 | PubMed
  66. Prognostic assay in small, node-negative non-small cell lung cancer--reply.
    2013 | PubMed
  67. The role of stem cells in airway repair: implications for the origins of lung cancer.
    2012 | PubMed
  68. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.
    2012 | PubMed
  69. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
    2012 | PubMed
  70. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
    2012 | PubMed
  71. IL11 is prognostic of survival in lung adenocarcinoma.
    2011 | UCSF Research Profile
  72. Child neurology: Brachial plexus birth injury: what every neurologist needs to know.
    2011 | PubMed
  73. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.
    2011 | PubMed
  74. Cancer stem cells in lung tumorigenesis.
    2010 | PubMed
  75. Genomic prognostic models in early-stage lung cancer.
    2009 | PubMed
  76. Anal canal duplication associated with presacral cyst.
    2008 | PubMed
  77. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2.
    2005 | PubMed
  78. Fluid Mechanical Forces as Extrinsic Modifiers of Endothelial Function.
    2005 | UCSF Research Profile
  79. Clinical pulmonary autograft valves: pathologic evidence of adaptive remodeling in the aortic site.
    2004 | PubMed
  80. Catalysis of peptide dissociation from class II MHC-peptide complexes.
    1999 | PubMed
  81. A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells.
    2021 | PubMed
  82. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
    2020 | PubMed
  83. Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
    2019 | PubMed
  84. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    2019 | PubMed
  85. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.
    2019 | PubMed
  86. Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model.
    2019 | PubMed
  87. Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10.
    2019 | PubMed
  88. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
    2018 | PubMed
  89. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    2018 | PubMed
  90. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.
    2018 | PubMed
  91. YAP regulates PD-L1 expression in human NSCLC cells.
    2017 | PubMed
  92. Hippo pathway in lung development.
    2017 | PubMed
  93. Drug development against the hippo pathway in mesothelioma.
    2017 | PubMed
  94. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
    2017 | PubMed
  95. Targeting YAP in malignant pleural mesothelioma.
    2017 | PubMed
  96. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
    2017 | PubMed
  97. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
    2016 | PubMed
  98. Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells.
    2016 | PubMed
  99. Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells.
    2015 | PubMed
  100. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.
    2015 | PubMed
  101. Analysis of lung tumor initiation and progression in transgenic mice for Cre-inducible overexpression of Cul4A gene.
    2015 | PubMed
  102. Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms.
    2015 | PubMed
  103. PR-Set7 is Degraded in a Conditional Cul4A Transgenic Mouse Model of Lung Cancer.
    2015 | PubMed
  104. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
    2015 | PubMed
  105. CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
    2014 | PubMed
  106. An alternative way to initiate Notch1 signaling in non-small cell lung cancer.
    2014 | PubMed
  107. Lung tumourigenesis in a conditional Cul4A transgenic mouse model.
    2014 | PubMed
  108. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression.
    2013 | PubMed
  109. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model.
    2013 | PubMed
  110. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
    2013 | PubMed
  111. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer.
    2013 | PubMed
  112. Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells.
    2013 | PubMed
  113. Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells.
    2012 | PubMed
  114. The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma.
    2012 | PubMed
  115. Transgenic mice for cre-inducible overexpression of the Cul4A gene.
    2011 | PubMed
  116. Cul4A is an oncogene in malignant pleural mesothelioma.
    2011 | PubMed
  117. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
    2011 | PubMed
  118. Adenovirus-mediated SOCS3 gene transfer inhibits the growth and enhances the radiosensitivity of human non-small cell lung cancer cells.
    2010 | PubMed
  119. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.
    2010 | PubMed
  120. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells.
    2009 | PubMed
  121. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells.
    2009 | PubMed
  122. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.
    2009 | PubMed
  123. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.
    2008 | PubMed
  124. Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription.
    2008 | PubMed
  125. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
    2007 | PubMed
  126. Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth.
    2007 | PubMed
  127. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells.
    2007 | PubMed
  128. Roles of secreted frizzled-related proteins in cancer.
    2007 | PubMed
  129. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth.
    2007 | PubMed
  130. Wnt inhibitory factor inhibits lung cancer cell growth.
    2007 | PubMed
  131. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.
    2007 | PubMed
  132. Stathmin is overexpressed in malignant mesothelioma.
    2007 | PubMed
  133. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
    2006 | PubMed
  134. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines.
    2006 | PubMed
  135. Wnt-1 signal as a potential cancer therapeutic target.
    2006 | PubMed
  136. The role of Wnt signaling in cancer and stem cells.
    2005 | PubMed
  137. Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
    2005 | PubMed
  138. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis.
    2005 | PubMed
  139. Wnt signaling in stem cells and non-small-cell lung cancer.
    2005 | PubMed
  140. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells.
    2005 | PubMed
  141. Wnt signaling in lung cancer.
    2005 | PubMed
  142. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.
    2005 | PubMed
  143. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
    2005 | PubMed
  144. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma.
    2004 | PubMed
  145. Cloning and characterization of the promoter of human Wnt inhibitory factor-1.
    2004 | PubMed
  146. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma.
    2004 | PubMed
  147. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.
    2004 | PubMed
  148. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.
    2004 | PubMed
  149. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
    2004 | PubMed
  150. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
    2004 | PubMed
  151. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells.
    2004 | PubMed
  152. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
    2004 | PubMed
  153. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells.
    2004 | PubMed
  154. Future directions: oncolytic viruses.
    2004 | PubMed
  155. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
    2003 | PubMed
  156. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.
    2003 | PubMed
  157. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.
    2003 | PubMed
  158. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q.
    2003 | PubMed
  159. Cloning and characterization of a functional promoter of the human SOCS-3 gene.
    2003 | PubMed
  160. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells.
    2003 | PubMed
  161. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
    2002 | PubMed
  162. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.
    2001 | PubMed
  163. A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens.
    2001 | PubMed
  164. Indomethacin reduces lung adenoma number in A/J mice.
    2001 | PubMed
  165. Identification of differentially expressed nucleolar TGF-beta1 target (DENTT) in human lung cancer cells that is a new member of the TSPY/SET/NAP-1 superfamily.
    2001 | PubMed
  166. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.
    2001 | PubMed
  167. Stage II (N1) lung cancer.
    2001 | PubMed
  168. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells.
    2000 | PubMed
  169. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
    2000 | PubMed
  170. Transforming growth factor-beta expression in mouse lung carcinogenesis.
    1998 | PubMed
  171. Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
    1998 | PubMed
  172. Identification of early growth response gene-1 (Egr-1) as a phorbol myristate acetate-induced gene in lung cancer cells by differential mRNA display.
    1997 | PubMed
  173. Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells.
    1997 | PubMed
  174. Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells.
    1997 | PubMed
  175. Carcinogenicity, DNA adduct formation and K-ras activation by 7H-dibenzo[c,g]carbazole in strain A/J mouse lung.
    1996 | PubMed
  176. Frameshift mutation in codon 176 of the p53 gene in rat esophageal epithelial cells transformed by benzo[a]pyrene dihydrodiol.
    1995 | PubMed
  177. Tumor multiplicity, DNA adducts and K-ras mutation pattern of 5-methylchrysene in strain A/J mouse lung.
    1994 | PubMed
  178. Allele-specific activation and expression of the K-ras gene in hybrid mouse lung tumors induced by chemical carcinogens.
    1994 | PubMed
  179. Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids.
    1992 | PubMed
  180. Activation of protooncogenes in mouse lung tumors.
    1991 | PubMed